Intellectual property rights, especially patents, frequently form the foundation of value in a life sciences company. If conducted with eventual commercial success in mind, a due diligence review of an IP portfolio can enable an investor to assess more accurately the present and future value of the technology and IP associated with an investment. Often times however, little thought is given as to how to leverage the harvested intelligence in the commercialization process of the acquired technology after the deal. This panel discussed:
- The IP due diligence process – what to expect and preparing for the unexpected
- Working the IP – identifying and valuing know-how to execute the IP
- The technology factor – working with R & D during and after the diligence process
Related Insights
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…
July 23, 2025
Health Care Law Today
Update: CMS Extends Skilled Nursing Facilities’ Medicare Revalidation Deadline
On April 17, 2025, the Centers for Medicare and Medicaid Services (CMS) announced another extension of the deadline by which skilled nursing facilities (SNFs) must revalidate their Medicare enrollments.
July 22, 2025
Health Care Law Today
GLP-1 Receptor Agonists: Clinical Trial Considerations
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®).